90 related articles for article (PubMed ID: 36743312)
21. Metabolomics and lipidomics in non-small cell lung cancer.
Shi W; Cheng Y; Zhu H; Zhao L
Clin Chim Acta; 2024 Mar; 555():117823. PubMed ID: 38325713
[TBL] [Abstract][Full Text] [Related]
22. Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma.
Fahrmann JF; Grapov DD; Wanichthanarak K; DeFelice BC; Salemi MR; Rom WN; Gandara DR; Phinney BS; Fiehn O; Pass H; Miyamoto S
Carcinogenesis; 2017 Mar; 38(3):271-280. PubMed ID: 28049629
[TBL] [Abstract][Full Text] [Related]
23. Combined analysis of gut microbiome and serum metabolomics reveals novel biomarkers in patients with early-stage non-small cell lung cancer.
Ni B; Kong X; Yan Y; Fu B; Zhou F; Xu S
Front Cell Infect Microbiol; 2023; 13():1091825. PubMed ID: 36743312
[TBL] [Abstract][Full Text] [Related]
24. Gut microbiota and its metabolites in non-small cell lung cancer and brain metastasis: from alteration to potential microbial markers and drug targets.
Jiang H; Zeng W; Zhang X; Li Y; Wang Y; Peng A; Cao D
Front Cell Infect Microbiol; 2023; 13():1211855. PubMed ID: 38304459
[TBL] [Abstract][Full Text] [Related]
25. Serum untargeted metabolomics reveal metabolic alteration of non-small cell lung cancer and refine disease detection.
Li J; Liu K; Ji Z; Wang Y; Yin T; Long T; Shen Y; Cheng L
Cancer Sci; 2023 Feb; 114(2):680-689. PubMed ID: 36310111
[TBL] [Abstract][Full Text] [Related]
26. Combined metabolomics with transcriptomics reveals potential plasma biomarkers correlated with non-small-cell lung cancer proliferation through the Akt pathway.
Zheng J; Zheng Y; Li W; Zhi J; Huang X; Zhu W; Liu Z; Gong L
Clin Chim Acta; 2022 May; 530():66-73. PubMed ID: 35245482
[TBL] [Abstract][Full Text] [Related]
27. Assessment of plasma amino acids, purines, tricarboxylic acid cycle metabolites, and lipids levels in NSCLC patients based on LC-MS/MS quantification.
Cang S; Liu R; Mu K; Tang Q; Cui H; Bi K; Zhang Y; Li Q
J Pharm Biomed Anal; 2022 Nov; 221():114990. PubMed ID: 36208488
[TBL] [Abstract][Full Text] [Related]
28. Dysbiosis of the Gut Microbiome Is Associated With Histopathology of Lung Cancer.
Qin X; Bi L; Yang W; He Y; Gu Y; Yang Y; Gong Y; Wang Y; Yan X; Xu L; Xiao H; Jiao L
Front Microbiol; 2022; 13():918823. PubMed ID: 35774470
[TBL] [Abstract][Full Text] [Related]
29. Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
Martini G; Ciardiello D; Dallio M; Famiglietti V; Esposito L; Corte CMD; Napolitano S; Fasano M; Gravina AG; Romano M; Loguercio C; Federico A; Maiello E; Tuccillo C; Morgillo F; Troiani T; Di Maio M; Martinelli E; Ciardiello F
Int J Cancer; 2022 Aug; 151(3):473-480. PubMed ID: 35429341
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and predictive value of the newly proposed grading system of invasive pulmonary adenocarcinoma in Chinese patients: a retrospective multicohort study.
Hou L; Wang T; Chen D; She Y; Deng J; Yang M; Zhang Y; Zhao M; Zhong Y; Ma M; Zhao G; Chen Y; Xie D; Zhu Y; Chen Q; Wu C; Chen C;
Mod Pathol; 2022 Jun; 35(6):749-756. PubMed ID: 35013526
[TBL] [Abstract][Full Text] [Related]
31. Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant Metastasis.
Lu H; Gao NL; Tong F; Wang J; Li H; Zhang R; Ma H; Yang N; Zhang Y; Wang Y; Liang Z; Zeng H; Chen WH; Dong X
Microbiol Spectr; 2021 Dec; 9(3):e0080221. PubMed ID: 34787462
[TBL] [Abstract][Full Text] [Related]
32. Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma.
Nie M; Yao K; Zhu X; Chen N; Xiao N; Wang Y; Peng B; Yao L; Li P; Zhang P; Hu Z
Nat Commun; 2021 Nov; 12(1):6479. PubMed ID: 34759281
[TBL] [Abstract][Full Text] [Related]
33. Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients.
Zhao F; An R; Wang L; Shan J; Wang X
Front Cell Infect Microbiol; 2021; 11():725284. PubMed ID: 34527604
[TBL] [Abstract][Full Text] [Related]
34. Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver Mutations.
Deng C; Zheng Q; Zhang Y; Jin Y; Shen X; Nie X; Fu F; Ma X; Ma Z; Wen Z; Wang S; Li Y; Chen H
J Thorac Oncol; 2021 Oct; 16(10):1684-1693. PubMed ID: 34302987
[TBL] [Abstract][Full Text] [Related]
35. A circular network of coregulated sphingolipids dictates lung cancer growth and progression.
Meng Q; Hu X; Zhao X; Kong X; Meng YM; Chen Y; Su L; Jiang X; Qiu X; Huang C; Liu C; Wang M; Wong PP
EBioMedicine; 2021 Apr; 66():103301. PubMed ID: 33813137
[TBL] [Abstract][Full Text] [Related]
36. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
Hakozaki T; Richard C; Elkrief A; Hosomi Y; Benlaïfaoui M; Mimpen I; Terrisse S; Derosa L; Zitvogel L; Routy B; Okuma Y
Cancer Immunol Res; 2020 Oct; 8(10):1243-1250. PubMed ID: 32847937
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
